Half-dose for Halcygen
Tuesday, 07 October, 2008
Halcygen Pharmaceuticals (ASX: HGN) has demonstrated the effectiveness of the company's SUBA-itraconazole antifungal in a recent pharmacokinetic trial.
The trial was the first of three pharmacokinetic studies the company is conducting for the Investigational New Drug [IND] application recently approved by the FDA.
Halcygen was able to prove that SUBA-itraconazole in a 'half-dose' format gives comparable pharmacokinetic levels to a full dose of itraconazole market leader Sporanox.
All three pharmacokinetic trials should be complete by the end of the year.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
